Neuroprotective peptides

Details Neuroprotective peptides Neuroprotective peptides

2007-08-21

2007-08-21

Weber, Jon (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S015800, C530S326000, C530S327000, C435S070100

Reexamination Certificate

active

09863600

ABSTRACT:
Methods of treating diseases of the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin are disclosed. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. Improved therapeutic regimens where the erythropoietin is administered at concentrations below those required to stimulate hematopoiesis are also provided.

REFERENCES:
patent: 5221607 (1993-06-01), Cordell et al.
patent: 5252463 (1993-10-01), Nelson et al.
patent: 5571787 (1996-11-01), O'Brien et al.
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5688679 (1997-11-01), Powell
patent: 5696080 (1997-12-01), O'Brien et al.
patent: 5700909 (1997-12-01), O'Brien
patent: 5714459 (1998-02-01), O'Brien et al.
patent: 5767078 (1998-06-01), Johnson et al.
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5986047 (1999-11-01), Wrighton et al.
patent: 6165783 (2000-12-01), Weiss
patent: 640619 (1997-07-01), None
patent: WO94/12650 (1994-06-01), None
patent: WO95/03821 (1994-06-01), None
patent: 96/40749 (1996-12-01), None
patent: WO99/05268 (1999-02-01), None
patent: WO99/1781 (1999-03-01), None
patent: WO 99/21966 (1999-05-01), None
patent: WO99/21966 (1999-05-01), None
patent: WO99/38890 (1999-08-01), None
patent: WO 00/24782 (2000-05-01), None
patent: 04/100997 (2004-05-01), None
patent: 04/101606 (2004-11-01), None
patent: 04/101611 (2004-11-01), None
Ezzell, Scientific America, pp. 152-153, Mar. 7, 1993.
Varon et al., Dev. Neurosci., vol. 6, pp. 73-100, 1983/1984.
Johnson et al., Biochemistry, vol. 37, pp. 3699-3710, 1998.
Campana et al., International Journal of Molecular Medicine, vol. 1, pp. 235-241, 1998.
Bernaudin et al., Journal of Cerebral Blood Flow and Metabolism, vol. 19, pp. 643-651, 1999.
Sakanaka et al., in vivo evidence that erythropoietin protects neurons from ischemic damage, Apr. 1998, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 4635-4640.
B. S. Beckman and M. Mason-Garcia, “Signal Transduction in Erythropoiesis”,The Faseb Journal(1991) 5(14): 2958-2964).
Bernaudin et al., “A Potential Role for Erythropoietin in Focal Permanent Cerebral Ischemia in Mice”,J. Cereb. Blood Flow Metab.(1999) 19:643-51.
Brint et al., “Focal Brain Ischemia in the Rat Methods for Reproducible Neocortical Infarction Using Tandem Occlusion of the Distal Middle Cerebral and Ipsilateral Common Cortoid Arteries”,J. Cereb. Blood Flow Metab.(1988) 8(4):474-485.
Campana et al., “Identification of a Neurotrophic Sequence of Erythropoietin”,Inter. J. Mol. Med.(1998) 1:235-241.
Eschbach et al., “Correction of the Anemia of End-stage Renal Disease with Recombinant Human Erythropoietin: Results of a Combined Phase I and II Clinical Trial”,New Engl. J. Med.(1987) 316(2): 73-78.
Genc et al., “Erythropoietin Exerts Neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin-treated C57/BL Mice Via Increasing Nitric Oxide Production”,Neuroscience Letters(2001) 298:139-141.
Johnson et al., “Identification ofa 13 Amino Acid Peptide Mimeric of Erythropoietin and Description of Amino Acids Critical for the Mimetic Activity of EMP1”,Biochemistry(1998) 37:3699-3710.
Johnson et al., “Amino-Terminal Dimerization of an Erythropoietin Mimetic Peptide Results in Increased Erythropoietic Activity”,Chemistry&Biology(1997) 4(12):939-950.
Juul et al., “Immunohistochemical Localization of Erythropoietin and its Receptors in the Developing Human Brain”,Pediatr. Dev. Pathol.(1999) 2(2):148-158.
Juul et al. Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System,Pedr. Res.(1998) 43(1):40-49.
Juul et al., “Erythropoietin in the Cerebrospinal Fluid of Neonates who Sustained CNS Injury”,Ped. Res.(1999) 46:(5):543-547.
Konishi et al., “Trophic Effect of Erythropoietin and Other Hematopoietic Factors on Central Cholinergic Neurons In Vitro and In Vivo”,Brain Res.(1993) 609:29-35.
Koshimura et al., “Effects of Erythropoietin on Neuronal Activity”,J. Neurochem.(1999) 72(6):2565-2572.
Sanford B. Krantz et al., “Erythropoietin”,Blood77(3): 419-434.
Marti et al., “Detection of Erythropoietin in Human Liquor: Intrinsic Erythropoietin Production in the Brain”,Kidney Int.(1997) 51(2):416-418.
Masuda et al., “A Novel Site of Erythropoietin Production: Oxygen-Dependent Production in Cultured Rat Astrocytes”,J. Biol. Chem.(1994) 269(30):19488-19493.
Mattson et al., “Calcium, Free Radical and Excitotoxic Neuronal Death in Primary Cell Culture”,Methods Cell Biol.(1994) 46:187-216.
Morishita et al., “Erythropoietin Receptor is Expressed in Rat Hippocampal and Cerebral Cortical Neurons, and Erythropoietin Prevent In Vitro Glutamate-Induced Neuronal Death”,Neurosci.(1997) 76(1):105-116.
Nakamura et al., “Elevated Levels of Erythropoietin in Cerbrospinal Fluid of Depressed Patients”,Amer. J. Med. Sci.(1998) 315:199-201.
Sadamoto et al., “Erythropoietin Prevent Place Navigation Disability and Cortical Infarction in Rats with Permanent Occlusion of the Middle Cerebral Artery”,Biochem. Biophys.Res. Comm.(1998) 253:26-32; Article No. RC989748.
Sakanaka et al., “In VivoEvidence that Erythropoietin Protects Neurons from Ischemic Damage”,Proc. Natl. Acad. Sci.(1998) 95:4635-4640.
Silva et al., “Erythropoietin Can Promote Erythroid Progenitor Survival by Repressing Apoptosis Through Bcl-XLand Bcl-2”,Blood(1996) 88(5):1576-1582.
Smith-Swintosky et al., “Protease-Activated Receptor 2 (PAR-2) is Present in the Rat Hippocampus and is Associated with Neurodegeneration”,J. Neurochem., (1997) 69:1890-1896.
Tabira et al., “Neurotrophic Effect of Hematopoietc Cytokines on Cholinergic and Other Neurons In Vitro”,Int. J. Dev. Neurosci.(1995) 13(3/4):241-252.
Winerals et al., “Effect of Human Erythropoietin Derived From Recombinant DNA on the Anaemia of Patients Maintained by Chronic Haemodialysis”,Lancet(1986) 2(8517):1175-1177.
European Search Report dated Mar. 22, 2005 for corresponding Appln. No. EP 01941562.
Examiner's first report for Australian Patent Appln. No. 2001274904 dated Jun. 15, 2005.
Eur. J. Pharmacology (2000) 392(1-2): 31-4, “In Vivo Evidence that Erythropoietin had a Neuroprotective Effect During Subarachnoid Hemorrhage”, Buemi M, Grasso G, Corica F, Calapai G, Salpietro FM, Casucelli T. Sfacteria A Aloisi C, Alafaci Cm Sturiale A, Frisina N, Tomasell F, Mar. 24, 2000.

Affiliated with

Also associated with

Rating

Neuroprotective peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neuroprotective peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuroprotective peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3833587